共 391 条
[11]
Vogelzang NJ(2005)Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50 83-150
[12]
Porta C(2007)Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma Cancer Chemother Pharmacol 59 149-695
[13]
Mutti L(2004)A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM) J Clin Oncol 22 14-5484
[14]
Sørensen JB(2007)Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed Thorax 62 690-5882
[15]
Frank H(2002)Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res 62 5476-1972
[16]
Palshof T(2007)Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors Clin Cancer Res 13 5876-1661
[17]
Vogelzang NJ(2007)Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol Cancer Ther 6 1962-S8
[18]
Rusthoven JJ(2010)Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma Am J Clin Oncol 25 15-215
[19]
Symanowski J(2010)A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma J Natl Cancer Inst 28 15-2304
[20]
Denham C(2010)A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET J Natl Cancer Inst 28 15-2413